Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,491 | -12,799 | -96,132 | -65,907 | -48,083 |
| Depreciation Amortization | 396 | 199 | 658 | 466 | 265 |
| Accounts receivable | 27 | -14 | 21 | 66 | 79 |
| Accounts payable and accrued liabilities | -344 | -526 | -218 | 2,521 | -258 |
| Other Working Capital | 4,843 | 3,604 | -930 | 2,063 | -3,558 |
| Other Operating Activity | -8,395 | -8,707 | 17,769 | 3,459 | 8,930 |
| Operating Cash Flow | $-34,964 | $-18,243 | $-78,832 | $-57,332 | $-42,625 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -115 | -114 | -1,559 | -1,482 | -1,107 |
| Investing Cash Flow | $-115 | $-114 | $-1,559 | $-1,482 | $-1,107 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 955 | 952 | 49,530 | 49,530 | 49,410 |
| Common Stock Repurchased | -250 | -246 | -546 | -96 | N/A |
| Financing Cash Flow | $705 | $706 | $48,984 | $49,434 | $49,410 |
| Beginning Cash Position | 73,306 | 73,306 | 104,713 | 104,713 | 104,713 |
| End Cash Position | 38,932 | 55,655 | 73,306 | 95,333 | 110,391 |
| Net Cash Flow | $-34,374 | $-17,651 | $-31,407 | $-9,380 | $5,678 |
| Free Cash Flow | |||||
| Operating Cash Flow | -34,964 | -18,243 | -78,832 | -57,332 | -42,625 |
| Capital Expenditure | -115 | -114 | -1,559 | -1,482 | -1,107 |
| Free Cash Flow | -35,079 | -18,357 | -80,391 | -58,814 | -43,732 |